N-Caffeoyldopamine

• Description:

  N-Caffeoyldopamine (Compound 6i) is an amyloid-beta aggregation inhibitor. N-Caffeoyldopamine can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. N-Caffeoyldopamine can be used for Alzheimer's disease research[1].

• UNSPSC:

  12352005

• Target:

  Amyloid-β

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/aβ-in-9.html

• Purity:

  90.00

• Smiles:

  OC1=C(O)C=CC(CCNC(/C=C/C2=CC(O)=C(O)C=C2)=O)=C1

• Molecular Formula:

  C17H17NO5

• Molecular Weight:

  315.32

• References & Citations:

  [1]Xu F, et al. Synthesis and evaluation of catecholamine derivatives as amyloid-beta aggregation inhibitors. Bioorg Med Chem Lett. 2024 Jul 15;107:129788.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported